semaglutide
Kayshild, Ozempic, Rybelsus, Wegovy · ATC code A10BJ06
Also known as: Semaglutid
- Key facts
- Active substance
- semaglutide
- Drug class
- Glucagon-like peptide-1
- ATC code
- A10BJ06
- Authorisation
- centrally authorised across the EU (EMA)
- Dosage forms
- Kayshild 0.25 mg solution for injection in pre-filled pen / Kayshild 0.5 mg solution for injection in pre-filled pen / Kayshild 1 mg solution for injection in pre-filled pen · Ozempic 0.25 mg solution for injection in pre-filled pen / Ozempic 0.5 mg solution for injection in pre-filled pen / Ozempic 1 mg solution for injection in pre-filled pen · Rybelsus 1.5 mg tablets / Rybelsus 4 mg tablets / Rybelsus 9 mg tablets · Rybelsus 3 mg tablets / Rybelsus 7 mg tablets / Rybelsus 14 mg tablets · Wegovy 0.25 mg solution for injection in pre-filled pen / Wegovy 0.5 mg solution for injection in pre-filled pen / Wegovy 1 mg solution for injection in pre-filled pen · Wegovy 1.5 mg tablets / Wegovy 4 mg tablets / Wegovy 9 mg tablets
- Marketing authorisation holder
- Novo Nordisk A/S
- Information as of
- 2026-10-27
Key facts
Semaglutide is a GLP-1 receptor agonist. Depending on the product it is used for type 2 diabetes (Ozempic, Rybelsus), weight management (Wegovy) and MASH with liver fibrosis (Kayshild).
What it is used for
- Ozempic (injection) and Rybelsus (tablets): insufficiently controlled type 2 diabetes in adults, adjunct to diet and exercise, alone or in combination
- Wegovy: weight management in adults with BMI ≥ 30 kg/m2, or ≥ 27 kg/m2 with at least one weight-related comorbidity
- Wegovy injection: also adolescents aged 12 years and above with obesity and body weight above 60 kg
- Kayshild: non-cirrhotic MASH with moderate to advanced liver fibrosis (F2 to F3) in adults
Dosing
- Ozempic: start 0.25 mg once weekly, after 4 weeks 0.5 mg; if needed stepwise to 1 mg or 2 mg (maximum 2 mg weekly)
- Wegovy injection and Kayshild: escalation over 16 weeks from 0.25 mg to a maintenance dose of 2.4 mg once weekly; Wegovy may go to 7.2 mg in adults with BMI ≥ 30 kg/m2
- Rybelsus 1.5/4/9 mg: start 1.5 mg daily for one month, then 4 mg; Rybelsus 3/7/14 mg: start 3 mg, then 7 mg; maximum 50 mg daily
- Wegovy tablets: start 1.5 mg daily, escalating via 4 mg and 9 mg to 25 mg daily
- Tablets on an empty stomach with a sip of water; wait at least 30 minutes before eating, drinking or other oral medicines
- With a sulfonylurea or insulin: consider reducing their dose (hypoglycaemia risk)
Contraindications
- Hypersensitivity to the active substance or excipients
Important warnings
- Acute pancreatitis; discontinue if suspected and do not restart if confirmed
- Pulmonary aspiration risk with general anaesthesia or deep sedation due to delayed gastric emptying
- Gastrointestinal adverse reactions may cause dehydration and, rarely, deterioration of renal function
- Type 2 diabetes: diabetic retinopathy complications; not a substitute for insulin, not for diabetic ketoacidosis
Side effects
- Very common: nausea and diarrhoea; common vomiting, constipation, abdominal pain
- Gastrointestinal reactions are mostly mild or moderate, mainly during dose escalation
- Fatigue; hypoglycaemia when combined with insulin or a sulfonylurea
Interactions
- Delayed gastric emptying may affect absorption of oral medicines; caution with medicines that need rapid absorption
- Rybelsus: increased thyroxine exposure, consider monitoring thyroid parameters
- Insulin and sulfonylureas: increased hypoglycaemia risk
Pregnancy and breastfeeding
- Not to be used in pregnancy; discontinue at least 2 months before a planned pregnancy; contraception recommended
- Should not be used during breast-feeding (all products)
Summary of the official product information, written with AI (Claude, Anthropic) on 2026-10-28. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.
Common questions – ask Medelix
For patients
Package leaflet, verbatim
Authorisation and brand names by country
Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.
EU – centrally authorised (all member states)
- KayshildNovo Nordisk A/S · EMEA/H/C/006426
- OzempicNovo Nordisk A/S · EMEA/H/C/004174
- RybelsusNovo Nordisk A/S · EMEA/H/C/004953
- WegovyNovo Nordisk A/S · EMEA/H/C/005422
Source: European Medicines Agency (EMA), product information
Turkey
- OzempicNOVO NORDİSK SAĞLIK ÜRÜNLERİ TİC LTD. ŞTİ. · 5 register entries
- RybelsusNOVO NORDİSK SAĞLIK ÜRÜNLERİ TİC LTD. ŞTİ. · 9 register entries
- WegovyNOVO NORDİSK SAĞLIK ÜRÜNLERİ TİC LTD. ŞTİ. · 6 register entries
Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16
Brand names in 2 more European countries
- Iceland
- Kayshild, Ozempic, Rybelsus, Wegovy
- Norway
- Kayshild, Ozempic, Rybelsus, Wegovy
EMA – Article 57 product data (EU/EEA), 2026-10-28
Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.
Other substances in the same group
Related calculators
Another question about this substance?
Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.
Sources
- European Medicines Agency. Kayshild – EPAR, Product Information (OF THE TEXT Detailed information on this medicinal product i). 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/kayshild-epar-product-information_en.pdf
- European Medicines Agency. Ozempic – EPAR, Product Information (OF THE TEXT Detailed information on this medicinal product i). 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/ozempic-epar-product-information_en.pdf
- European Medicines Agency. Rybelsus – EPAR, Product Information (OF THE TEXT Detailed information on this medicinal product i). 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/rybelsus-epar-product-information_en.pdf
- European Medicines Agency. Wegovy – EPAR, Product Information (OF THE TEXT Detailed information on this medicinal product i). 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/wegovy-epar-product-information_en.pdf
- TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85
- Wikidata (CC0): ATC A10BJ.
Editorial: Medelix editorial team · last updated 2026-10-27 · How these pages are made · Report an error
Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.